U.S. stock market update: Klotho Neurosciences down 20.29%, with a surge in R&D expenses and setbacks in clinical trials hitting the stock price hard

U.S. Stock Market Midday Update Klotho Neurosciences fell 20.29%. Based on recent news, On March 2, Klotho Neurosciences released its latest financial report showing a significant increase in R&D expenses, leading to an expanded net loss. Investors are concerned about the company's future profitability, resulting in a sharp decline in stock price. On March 3, Klotho Neurosciences announced that a new clinical trial failed to meet its primary endpoint, disappointing the market regarding its R&D prospects and further pressuring the stock price. On March 3, analysts downgraded Klotho Neurosciences' rating, believing the company would struggle to achieve profitability in the short term, further undermining investor confidence. The biotechnology sector has been volatile recently, and investors should exercise caution. Stocks with High Trading Volume in the Industry Amgen fell 2.92%, with increased trading volume. Based on recent key news: On March 3, Amgen Executive Vice President Esteban Santos sold 54,792 shares of stock, totaling over $20.77 million. Such executive sell-offs are typically viewed as negative signals for the company's future performance, potentially leading to decreased investor confidence and a subsequent decline in stock price. Source: SEC announcement On March 3, Amgen and Kyowa Kirin jointly announced the termination of the Rocatinlimab clinical trial due to potential risks outweighing benefits. This move could negatively impact Amgen's R&D prospects, putting pressure on the stock price. Source: Reuters On March 3, Oppenheimer analysts noted that historically, the stock market performs better in March than in February, but Amgen has failed to benefit from this trend and instead experienced a decline in stock price due to internal factors. Source: Oppenheimer analysis report. The biotechnology sector faces R&D risks and challenges from executive turnover. AbbVie fell 0.48%. Based on recent news, On March 2, AbbVie announced positive results from its Phase 3 AFFIRM study, evaluating the subcutaneous induction efficacy of SKYRIZI® (risankizumab) in patients with Crohn's disease. The study showed that risankizumab achieved superiority at week 12, with safety consistent with known safety profiles for Crohn's disease, and no new safety risks were identified. This news had a positive impact on the stock price but did not fully offset the overall market decline. On March 3, AbbVie will participate in the Leerink Partners Global Healthcare Conference on March 10, with management participating in a fireside chat. Although this news indicates the company is actively engaging in industry events, its direct impact on the stock price is limited On March 2, AbbVie announced the topline data from its Phase 3 AFFIRM study, showing the potential of risankizumab in treating Crohn's disease. 55% of patients achieved clinical remission by week 12, compared to 30% in the placebo group. This result demonstrates the potential of risankizumab as a leading treatment for Crohn's disease, but the market reaction was relatively muted. The healthcare sector outperformed the market last week, showing strong momentum. Gilead Sciences fell 2.48%. Based on recent key news: On March 2, Gilead Sciences CEO Daniel Patrick O’Day sold company common stock, raising concerns in the market about internal confidence, leading to a decline in stock price. According to disclosures from the SEC's EDGAR system, the sale was completed on March 2. On March 2, the Gilead Foundation announced a grant of $12 million for community health workers and to expand HIV prevention programs. Although this move demonstrates the company's social responsibility, it failed to boost the stock price. On March 3, Gilead's collaboration project with AstraZeneca received non-dilutive financing, expected to support its R&D pipeline through 2029. Although this news indicates the company's financial stability, it did not reverse the stock price decline. Market volatility has increased, and macroeconomic risks need to be monitored. Stocks ranked among the top in industry market capitalization Forte Biosciences fell 2.54%. Based on recent news: On March 2, Forte Biosciences announced that it does not intend to update or revise any forward-looking statements. This announcement may have raised market concerns about the company's future development, leading to a decline in stock price. On March 3, Forte Biosciences announced it would participate in a non-deal roadshow hosted by SinoPac Security and Auerbach Grayson in New York and Boston, planning to discuss operational performance and future outlook. Although this news shows the company is actively communicating with investors, it failed to boost the stock price. On March 3, analysts maintained a "Hold" rating on Forte Biosciences, with a target price of $0.96. Concerns from analysts regarding corporate governance and long-term strategic direction may further dampen market confidence. The pharmaceutical industry has recently shown weak performance, and investor sentiment remains cautious